Lv5
945 积分 2021-06-04 加入
The evolving landscape of drug targets
5天前
已完结
NLRP3 inhibition by VTX3232 tempers inflammation resulting in reduced body weight, hyperglycemia, and hepatic steatosis in obese male mice
8天前
已完结
Discovery of 2-(6-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4,5-dimethylpyridazin-3-yl)-5-(trifluoromethyl)phenol (ASP0965): A potent, orally active and brain-penetrable NLRP3 inflammasome inhibitor with a novel scaffold for the treatment of α-synucleinopathy
8天前
已完结
Solute carrier membrane transporters: emerging targets in CNS disorders
8天前
已完结
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities
8天前
已完结
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety
8天前
已完结
Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an in vivo tool compound for neuroinflammatory disorders
8天前
已完结
Chemoproteomic discovery of a brain‐penetrant, covalent NLRP3 inhibitor that binds a novel allosteric pocket
8天前
已完结
Parkinson’s Disease
13天前
已完结
Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis
1个月前
已完结
皖公网安备34019202002308
